Inventaire - your friends and communities are your best library

Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.

author

Gabriella Misso

Daniele Pepe

Davide Gentilini

Elisa S. Grassi

Maria Orietta Borghi

Michele Caraglia

2000 -

published in: Molecular Oncology

date of publication: 2017-06-21

main subject: thyroid carcinoma

Cites articles 51

Date

Title

Authors

2016-09-12

Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors

Cristina Montero-Conde, Agustin F. Fernandez, Maria Santacana, Lucia Inglada-Pérez, Esmeralda Castelblanco, Mario Encinas, Mercedes Robledo, Xavier Matias-Guiu Guia, Mario F Fraga, Veronika Mancikova, Javier Perales-Patón, Salud Borrego
2016-06-14

Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy

Giovanni Vitale, Antongiulio Faggiano, Annamaria Colao
2016-05-21

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

Juliann Chmielecki, Jo-Anne Vergilio
2015-07-29

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Henk-Jan Guchelaar, Ellen Kapiteijn
2015-02-01

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
2014-01-01

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Guillermo Crespo, Felipe Fierro Maya, Peter Igaz
2014-09-28

Comprehensive analysis of DNA methylation data with RnBeads

Christoph Bock, Thomas Lengauer, Jörn Walter
2014-08-13

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy

Michele Caraglia, Luca Persani
2014-09-01

Targeting the mTOR signaling pathway in neuroendocrine tumors
2014-06-16

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.

Roman A Blaheta
2014-01-01

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment

Jan Scicinski
2014-05-06

Investigating perturbed pathway modules from gene expression data via structural equation models

Daniele Pepe
2014-04-01

The role of nerve growth factor and its receptors in tumorigenesis and cancer pain
2014-01-28

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

Kasper D. Hansen, Andrew P. Feinberg, Christine Ladd-Acosta, Andrew E Jaffe, Rafael Irizarry, Martin J. Aryee
2014-08-27

mTOR activation in medullary thyroid carcinoma with RAS mutation.

João Vinagre, Hugo Prazeres, Catarina Eloy, Manuel Sobrinho Simões, Paula Soares, Rui Batista, Vasco Sampaio-Pinto, Joana Lyra
2014-09-22

Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer

Lekun Fang
2013-07-18

DNA methylation and apoptosis resistance in cancer cells

Eric Hervouet, Pierre-Francois Cartron
2013-08-21

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells

Iñigo Landa, Jeffrey A Knauf
2013-09-19

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes

Kee-Hyun Nam, Sang-Wook Kang, Mijin Yun, Hwan Jung Yun, Byoung Chul Cho
2012-12-24

Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest
2012-05-08

Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells

Roman A Blaheta
2012-01-01

The neurotrophin family of neurotrophic factors: an overview
2012-07-01

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Michele Caraglia, Antongiulio Faggiano, Sara Castiglioni, Maria Orietta Borghi, Piero Ferolla, Diego Ferone, Annamaria Colao
2012-07-01

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma

Ashley Grossman
2011-08-17

The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells

Michele Caraglia, Maria Condello, Sara Castiglioni, Paola Maroni, Alfredo Budillon
2011-03-29

Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
2011-04-01

p75(NTR) induces apoptosis in medulloblastoma cells

Thomas Mikeska, Jan Küchler
2010-04-26

p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor-alpha-converting enzyme/ADAM17.
2009-01-01

Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems
2009-02-20

Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer
2008-11-05

A novel signaling pathway impact analysis

Sorin Draghici, Roberto Romero, Pooja Mittal, Sonia S Hassan, Purvesh Khatri, Chong Jai Kim, Juan Pedro Kusanovic, Adi Laurentiu Tarca
2008-05-06

The inhibitory effect of p75 neurotrophin receptor on growth of human hepatocellular carcinoma cells

Article - wd:Q41194522

Welcome to Inventaire

the library of your friends and communities

learn more